Effectiveness and safety of naftopidil for benign prostatic hyperplasia patients with overactive bladder symptoms / 中华男科学杂志
National Journal of Andrology
;
(12): 927-930, 2008.
Article
in Chinese
| WPRIM
| ID: wpr-309744
ABSTRACT
<p><b>OBJECTIVE</b>To assess the effectiveness and safety of the alphala/d blocker naftopidil in the treatment of benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms.</p><p><b>METHODS</b>Fifty BPH patients with OAB symptoms were treated with naftopidil at the dose of 25 mg/d for 6 weeks. A self-controlled clinical trial was conducted. The effectiveness and safety of the drug were observed by comparing the International Prostate Symptom Scores (IPSS), quality of life indexes (QOL), maximum urinary flow rates (Qmax) , average urinary flow rates (Qave), voiding volumes (VV), blood pressures (BP) and heart rates (HR) obtained before and after the treatment.</p><p><b>RESULTS</b>After 6 weeks' medication, the 46 assessable cases showed an average decrease of 9.75 in IPSS (P < 0.01), 3.97 in voiding symptom score (P < 0.01), 5.78 in urinary storage symptom score (P < 0.01) and 1.95 in QOL (P < 0.01), and a mean increase of 4.29 ml/s in Qmax (P < 0.01), 3.75 ml/s in Qave (P < 0.01) and 55.12 ml/s in VV (P < 0.05). But no significant changes were observed in BP and HR. Only 1 patient (4.35%) experienced the adverse event of dizziness.</p><p><b>CONCLUSION</b>The alphalA/D blocker naftopidil is both effective and safe in the treatment of BPH patients with OAB symptoms.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Piperazines
/
Prostatic Hyperplasia
/
Adrenergic alpha-Antagonists
/
Therapeutic Uses
/
Drug Therapy
/
Urinary Bladder, Overactive
/
Naphthalenes
Type of study:
Controlled clinical trial
Limits:
Aged
/
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS